Atossa Therapeutics Inc. (NASDAQ:ATOS) has a beta value of 2.23 and has seen 15,150,283 shares traded in the last trading session. The company, currently valued at $281.52 Million, closed the last trade at $2.33 per share which meant it gained $0.01 on the day or 0.43% during that session. The ATOS stock price is -118.03% off its 52-week high price of $5.08 and 65.24% above the 52-week low of $0.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 7.46 Million shares traded. The 3-month trading volume is 24.63 Million shares.
The consensus among analysts is that Atossa Therapeutics Inc. (ATOS) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.
Atossa Therapeutics Inc. (NASDAQ:ATOS) trade information
Sporting 0.43% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Apr 29 when the ATOS stock price touched $2.67-1 or saw a rise of 12.73%. Year-to-date, Atossa Therapeutics Inc. shares have moved 145.26%, while the 5-day performance has seen it change 31.64%. Over the past 30 days, the shares of Atossa Therapeutics Inc. (NASDAQ:ATOS) have changed 13.66%. Short interest in the company has seen 10.49 Million shares shorted with days to cover at 0.43.
Wall Street analysts have a consensus price target for the stock at $6.38, which means that the shares’ value could jump 173.82% from current levels. The projected low price target is $5 while the price target rests at a high of $7.75. In that case, then, we find that the current price level is +232.62% off the targeted high while a plunge would see the stock lose 114.59% from current levels.
Atossa Therapeutics Inc. (ATOS) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +52.4% over the past 5 years. Earnings growth for 2021 is a modest +2.7%.
Atossa Therapeutics Inc. (NASDAQ:ATOS)’s Major holders
Insiders own 0.04% of the company shares, while shares held by institutions stand at 7.7% with a share float percentage of 7.7%. Investors are also buoyed by the number of investors in a company, with Atossa Therapeutics Inc. having a total of 24 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc. (The) with over 518.11 Thousand shares worth more than $492.2 Thousand. As of December 30, 2020, Vanguard Group Inc. (The) held 0.43% of shares outstanding.
The other major institutional holder is Renaissance Technologies, LLC, with the holding of over 492.8 Thousand shares as of December 30, 2020. The firm’s total holdings are worth over $468.16 Thousand and represent 0.41% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of December 30, 2020, the former fund manager holds about 0.33% shares in the company for having 397420 shares of worth $377.55 Thousand while later fund manager owns 120.69 Thousand shares of worth $114.65 Thousand as of December 30, 2020, which makes it owner of about 0.1% of company’s outstanding stock.